- Home
- DAWN vs REPX Comparison
DAWN vs REPX Comparison
Compare DAWN & REPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- REPX
- Stock Information
- Founded
- DAWN 2018
- REPX 2016
- Country
- DAWN United States
- REPX United States
- Employees
- DAWN N/A
- REPX N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- REPX Oil & Gas Production
- Sector
- DAWN Health Care
- REPX Energy
- Exchange
- DAWN Nasdaq
- REPX Nasdaq
- Market Cap
- DAWN 624.8M
- REPX 581.0M
- IPO Year
- DAWN 2021
- REPX N/A
- Fundamental
- Price
- DAWN $7.19
- REPX $28.22
- Analyst Decision
- DAWN Strong Buy
- REPX Strong Buy
- Analyst Count
- DAWN 7
- REPX 1
- Target Price
- DAWN $27.86
- REPX $47.00
- AVG Volume (30 Days)
- DAWN 1.1M
- REPX 113.6K
- Earning Date
- DAWN 10-29-2025
- REPX 11-05-2025
- Dividend Yield
- DAWN N/A
- REPX 5.44%
- EPS Growth
- DAWN N/A
- REPX N/A
- EPS
- DAWN N/A
- REPX 4.52
- Revenue
- DAWN $187,638,000.00
- REPX $392,885,000.00
- Revenue This Year
- DAWN $12.56
- REPX N/A
- Revenue Next Year
- DAWN $48.02
- REPX $9.48
- P/E Ratio
- DAWN N/A
- REPX $6.18
- Revenue Growth
- DAWN 2190.50
- REPX N/A
- 52 Week Low
- DAWN $5.64
- REPX $21.98
- 52 Week High
- DAWN $16.76
- REPX $37.55
- Technical
- Relative Strength Index (RSI)
- DAWN 52.01
- REPX 51.87
- Support Level
- DAWN $7.18
- REPX $26.92
- Resistance Level
- DAWN $7.58
- REPX $28.31
- Average True Range (ATR)
- DAWN 0.27
- REPX 0.92
- MACD
- DAWN -0.03
- REPX -0.13
- Stochastic Oscillator
- DAWN 33.92
- REPX 37.00
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.